Related Experiment Video
Updated: Aug 6, 2025
08:46
Implantation of Electrospun Vascular Grafts with Optimized Structure in a Rat Model
Published on: June 27, 2018
8.0K
Peritoneal pre-conditioning impacts long-term vascular graft patency and remodeling
Mahyar Sameti1, Mozhgan Shojaee1, Bayan M Saleh1
1Department of Biomedical, Chemical Engineering, and Science, Florida Institute of Technology, Melbourne, FL 32901, United States.
Biomaterials Advances
|March 22, 2023
Summary
Long-term studies reveal peritoneal pre-implantation significantly improves tissue-engineered vascular graft (TEVG) viability and patency in rodent models. This strategy mitigates adverse effects like intimal hyperplasia, crucial for clinical translation.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Vascular Surgery
Background:
- Small-animal models for tissue-engineered vascular grafts (TEVGs) often show limitations in long-term clinical translation.
- Poly(ε-caprolactone) (PCL) conduits perform well in short-term studies but can lead to intimal hyperplasia and calcification over longer periods.
- The pro-inflammatory response of TEVGs over extended durations requires further investigation.
Purpose of the Study:
- To evaluate the long-term efficacy of poly(ε-caprolactone) (PCL) based tissue-engineered vascular grafts (TEVGs) in a rodent model.
- To test the hypothesis that differences in pro-inflammatory responses of pure PCL conduits are consequential after long-term grafting.
- To assess the long-term benefits of a peritoneal pre-implantation strategy on TEVG outcomes.
Main Methods:
- Electrospun PCL conduits, with and without 10% collagen and/or peritoneal pre-implantation, were grafted into rat abdominal aortae for 10 months.
- Graft viability, patency rates, intimal hyperplasia, and cellular infiltration (CD80+, CD3+) were analyzed.
- Comparison between pure PCL and collagen/PCL conduits, with and without pre-implantation, was performed.
Main Results:
- Graft viability was reduced in control grafts without pre-implantation after 10 months, unlike shorter-term studies.
- Pre-implanted grafts demonstrated a 100% patency rate and significantly reduced intimal hyperplasia.
- While collagen/PCL conduits showed some differences in cellular response (e.g., fewer CD80+, CD3+ cells), only pre-implantation impacted overall graft viability.
Conclusions:
- Long-term rodent models are essential for accurately evaluating the viability of different TEVGs.
- Peritoneal pre-implantation is a beneficial strategy that enhances TEVG viability and patency, and reduces intimal hyperplasia.
- This study highlights the importance of pre-implantation strategies for improving the clinical applicability of TEVGs.
